• EVENT_ID: ID number given by me for reference between tables.
• APPLICATION_NUMBER: Number given by the FDA for the drug; can have multiple applications under one number.
• APPLICATION_TYPE:
• NDA: New Drug Application
• BLA: Biologics License Application
• CRL_DATE: The date the CRL was given.
• YEAR: The year the CRL was given.

Deficiencies were classified based on the primary issues identified by the FDA for each individual deficiency statement and the action required to resolve it.

Deficiencies were coded at the event level, allowing for analysis at both the deficiency level and the CRL (application) level.

• EVENT_ID
• DEFICIENCY_DOMAIN: Clinical, Nonclinical, CMC, Statistics, Regulatory, Patent Certifications

• RISK-BENEFIT: FDA determines that the overall benefits of the drug do not outweigh its risks despite evidence of efficacy and/or safety data.
• EFFICACY: Failure to demonstrate substantial evidence of effectiveness, including failure to meet primary endpoints or lack of adequate and well-controlled trials.
• SAFETY: Insufficient safety data, unacceptable adverse events, or inability to adequately characterize safety at proposed doses or populations.
• PHARMACOLOGY: Inadequate pharmacokinetic/pharmacodynamic (PK/PD), bioavailability, dose-response, or exposure data needed to support dosing, effectiveness, or safety.
• STUDY DESIGN: Flaws in trial design, including inappropriate endpoints, population selection, comparators, or trial structure that limit interpretability.
• DATA INTEGRITY: Issues with data reliability, including missing data, inconsistent datasets, protocol deviations, or inability to verify results.
• HUMAN FACTORS: Risks related to product use, including medication errors, labeling comprehension, device usability, or user interface issues.
• REDACTED: Clinical deficiency identified, but insufficient detail available (e.g. redacted CRLs).

• IMPURITY QUALIFICATION: Inadequate data to support safety of impurities or leachables exceeding regulatory thresholds.
• INSUFFICIENT NONCLINICAL SUPPORT: Missing or inadequate nonclinical studies required to support clinical use (general, not impurity-specific).
• TOXICOLOGY: Identified or potential toxic effects requiring additional toxicology studies or raising safety concerns.
• REDACTED: Nonclinical deficiency identified, but insufficient detail available (e.g. redacted CRLs).

• FACILITY: cGMP violations, inspection findings, or deficiencies related to manufacturing sites or facilities.
• MICROBIOLOGY: Issues related to sterility, microbial contamination, preservative effectiveness, or aseptic processing.
• STABILITY: Insufficient or inadequate stability data, including missing time points, batch data, or shelf-life justification.
• SPECIFICATIONS: Inadequate or missing acceptance criteria, test methods, or quality attribute limits (e.g., assay, impurities, strength).
• MANUFACTURING CONTROLS: Issues with manufacturing processes, validation, batch records, controls, or process consistency.
• BIOPHARMACEUTICS: Inadequate bridging, comparability, bioequivalence, or in vitro/in vivo performance linking to a reference product.
• REDACTED: CMC deficiency identified, but insufficient detail available (e.g. redacted CRLs).

• SAP (Statistical Analysis Plan) DEFICIENCIES: Issues with the statistical analysis plan, including lack of prespecification, multiplicity control, or improper statistical methodology.
• MISSING/INADEQUATE ANALYSES: Required analyses were not conducted, incomplete, or insufficiently reported.
• INSUFFICIENT EVIDENCE/NOT PERSUASIVE: Statistical results are inconclusive or not convincing, even if analyses were performed.
• REDACTED: Statistical deficiency identified, but insufficient detail available (e.g. redacted CRLs).

• ADMINISTRATIVE/FILING: Application deficiencies related to submission requirements or missing documentation.
• LABELING: Issues with prescribing information, formatting, or content of labeling.
• REMS/PMRs: Need for or inadequacy of risk management strategies or post-marketing requirements.
• PREA: Pediatric Study requirements not met.
• REDACTED: Regulatory deficiency identified, but insufficient detail available (e.g. redacted CRLs).

• PATENT CERTIFICATIONS: Issues related to patent certification requirements under regulatory pathways.